Stockscreener 앱 받기
59.17
3.39%
1.94
시간 외 거래:
58.86
-0.31
-0.52%
Gsk Plc Adr 주식(GSK)의 최신 뉴스
Teeth Whitening Products Market to Reach US$ 8.73 Billion by 2031 Driven by Rising Aesthetic Awareness, Social Media Influence, and Rapid Adoption of At-Home Whitening Solutions | Astute Analytica - GlobeNewswire Inc.
3 International Stocks to Buy for 2026 - morningstar.com
GSK Set up for Steady Long-Term Growth as Portfolio and Pipeline Develop - morningstar.com
GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook - TradingView
GSK plc (ADR): Quiet Rally, Loud Expectations – Is the Stock Finally Escaping Its Legal Overhang? - AD HOC NEWS
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
10 Best Blue-Chip Stocks to Buy for the Long Term - morningstar.com
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Oncolytic Virotherapy Market - GlobeNewswire Inc.
GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout - Finviz
GSK plc (ADR): Defensive pharma heavyweight tests investors’ patience as Wall Street edges cautiou - AD HOC NEWS
GSK To Acquire RAPT Therapeutics In $2.2 Billion Bet On Food Allergy Breakthrough - Sahm
GSK PLC Sponsored ADR (NYSE:GSK) Sees Significant Growth in Short Interest - MarketBeat
GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Recommendation of "Reduce" from Brokerages - MarketBeat
GSK plc (ADR): Defensive Pharma Giant Tests Investors’ Patience As Shares Slip Despite Solid Pipel - AD HOC NEWS
Jefferies Reaffirms a Buy Rating on GSK plc (GSK)Here's Why - Finviz
GSK's chronic hepatitis B drug meets goals in two late-stage studies - MSN
GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies - TradingView — Track All Markets
GSK (NYSE:GSK) Lowered to “Underweight” Rating by Barclays - Defense World
US Cuts Childhood Vaccine Schedule To 11 Core Shots— What It Means For Vaccine Makers Like Merck And GSK - Sahm
Flu Season's Here-This Dividend-Payer Controls the Shot Market - Finviz
The Truth About GSK plc (ADR): Viral Hype Or Sneaky Safe Bet For Your Portfolio? - AD HOC NEWS
The Truth About GSK plc (ADR): Is Wall Street Sleeping on This Pharma Beast? - AD HOC NEWS
GSK plc (ADR): Defensive Giant Or Underestimated Comeback Story? - AD HOC NEWS
GSK plc (ADR): Defensive Pharma Heavyweight Tests Investor Patience As Street Turns Selectively Bull - AD HOC NEWS
The Truth About GSK plc (ADR): Is This ‘Boring’ Stock Quietly Becoming a Power Play? - AD HOC NEWS
Drugmakers Plan Fresh Price Hikes On 350 Medicines In 2026 - Sahm
The Truth About GSK plc (ADR): Is Wall Street Sleeping On This Pharma Beast? - AD HOC NEWS
New Report Calls Achieve Life's Cytisinicline Best Therapy To Quit Smoking - Sahm
GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally - ts2.tech
The Market Is All In on the Magnificent Seven. Where Should Investors Look Next? - Morningstar
HSBC Sees Pharma Poised to Outperform in 2026, Lifts GSK Target - Finviz
Why is GSK plc (GSK) One of the Best Affordable Healthcare Stocks to Buy Now? - Finviz
Bard Financial Services Inc. Purchases 23,400 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK plc Sponsored ADR (GSK) Stock Price History & Data - Traders Union
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of “Hold” by Brokerages - Defense World
Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out - Sahm
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Brokerages - MarketBeat
Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK - Sahm
Douglas Lane & Associates LLC Sells 196,210 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
1.08%
2.15%
자본화:
|
볼륨(24시간):